128 related articles for article (PubMed ID: 2237825)
1. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double blind randomized study.
Rostagno C; Prisco D; Paniccia R; Costanzo G; Poggesi L; Boddi M; Abbate R
Thromb Res; 1990 Aug; 59(3):531-9. PubMed ID: 2237825
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil.
Rostagno C; Abbate R; Gensini GF; Coppo M; Prisco D; Boddi M; Neri Serneri GG
Thromb Res; 1991 Aug; 63(4):457-62. PubMed ID: 1754998
[No Abstract] [Full Text] [Related]
3. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
Johnson GJ; Leis LA; Francis GS
Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
[TBL] [Abstract][Full Text] [Related]
4. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.
Onoda JM; Sloane BF; Honn KV
Thromb Res; 1984 Jun; 34(5):367-78. PubMed ID: 6377570
[TBL] [Abstract][Full Text] [Related]
5. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619.
Johnson GJ; Leis LA; Francis GS
Thromb Res; 1990 Jul; 59(1):139-48. PubMed ID: 2399526
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation.
Yamada Y; Furui H; Furumichi T; Suzuki T; Yamauchi K; Yokota M; Hayashi H; Saito H
Jpn Heart J; 1990 Mar; 31(2):201-15. PubMed ID: 2113109
[TBL] [Abstract][Full Text] [Related]
7. Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism.
Mehta JL
Am J Cardiol; 1985 Jan; 55(3):158B-164B. PubMed ID: 2982252
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation.
Timar J; Chopra H; Rong X; Hatfield JS; Fligiel SE; Onoda JM; Taylor JD; Honn KV
J Cancer Res Clin Oncol; 1992; 118(6):425-34. PubMed ID: 1377695
[TBL] [Abstract][Full Text] [Related]
9. [Inhibition of platelet aggregation and thromboxane formation by the calcium antagonist nisoldipine following a single oral dose of 10 mg. A double-blind study in healthy probands].
Schrör K; Latta G; Darius H; Klaus W; Ziegler R
Klin Wochenschr; 1985 Jan; 63(1):16-9. PubMed ID: 3838352
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.
Moore JB; Fuller BL; Falotico R; Tolman EL
Thromb Res; 1985 Nov; 40(3):401-11. PubMed ID: 2417362
[TBL] [Abstract][Full Text] [Related]
11. Effects of diltiazem and verapamil on ADP-induced rabbit platelet shape change and aggregation.
Dehpour AR; Samadian T; Akhavan MM; Meysamee F; Delfan A
Gen Pharmacol; 1995 Oct; 26(6):1295-9. PubMed ID: 7590122
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
Kiyomoto A; Sasaki Y; Odawara A; Morita T
Circ Res; 1983 Feb; 52(2 Pt 2):I115-9. PubMed ID: 6831645
[TBL] [Abstract][Full Text] [Related]
13. Dual effects of nimesulide, a COX-2 inhibitor, in human platelets.
Saeed SA; Afzal MN; Shah BH
Life Sci; 1998; 63(20):1835-41. PubMed ID: 9820127
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers.
Valone FH
Thromb Res; 1987 Mar; 45(5):427-35. PubMed ID: 3590086
[TBL] [Abstract][Full Text] [Related]
15. Effects of verapamil on platelet aggregation, ATP release and thromboxane generation.
Mehta J; Mehta P; Ostrowski N; Crews F
Thromb Res; 1983 Jun; 30(5):469-75. PubMed ID: 6612680
[TBL] [Abstract][Full Text] [Related]
16. Membrane activity, antioxidant, antiaggregatory and antihemolytic properties of four calcium channel blockers.
Robak J; Duniec Z
Pharmacol Res Commun; 1986 Dec; 18(12):1107-17. PubMed ID: 3562505
[TBL] [Abstract][Full Text] [Related]
17. Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.
Jones CR; Pasanisi F; Elliott HL; Reid JL
Br J Clin Pharmacol; 1985 Sep; 20(3):191-6. PubMed ID: 2994701
[TBL] [Abstract][Full Text] [Related]
18. Effects of verapamil and diltiazem on human platelet function.
Addonizio VP; Fisher CA; Strauss JF; Wachtfogel YT; Colman RW; Josephson ME
Am J Physiol; 1986 Mar; 250(3 Pt 2):H366-71. PubMed ID: 3006516
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and quin2.
Ware JA; Johnson PC; Smith M; Salzman EW
Circ Res; 1986 Jul; 59(1):39-42. PubMed ID: 3089642
[TBL] [Abstract][Full Text] [Related]
20. Effect of calcium channel blockers on platelet GPIIb-IIIa as a calcium channel in liposomes: comparison with effects on the intact platelet.
Rybak ME; Renzulli LA
Thromb Haemost; 1992 Jan; 67(1):131-6. PubMed ID: 1319614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
